Two phase 3 trials to investigate faricimab for wet AMD

Roche and Genentech are initiating two phase 3 global trials to investigate the bispecific molecule faricimab for the treatment of wet age-related macular degeneration, according to a communication from Genentech.
Nearly 1,300 patients with wet AMD will be included in the two identically designed phase 3 TENAYA and LUCERNE studies. The studies will evaluate the safety, efficacy and durability of faricimab compared with Eylea (aflibercept, Regeneron) for the treatment of wet AMD.
Patients will be randomly assigned to receive faricimab dosed every 16 weeks, with an option to drop to (Read more...)

Full Story →